Kissei Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Mutsuo Kanzawa

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	42.4yrs
Eigendom CEO	3.5%
Management gemiddelde ambtstermijn	4.4yrs
Gemiddelde ambtstermijn bestuur	9.4yrs

Recente managementupdates

Recent updates

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Sep 24

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Sep 09

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Jul 25

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Jul 11

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

May 21

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

May 09

CEO

Mutsuo Kanzawa (75 yo)

42.4yrs

Tenure

Mr. Mutsuo Kanzawa is Chief Executive Officer of Kissei Pharmaceutical Co. Ltd and served as its President since June 1992. Mr. Kanzawa has been the Chairman of Kissei Pharmaceutical Co. Ltd. since June 20...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mutsuo Kanzawa	Chairman & CEO	no data	geen gegevens	3.49% ¥ 5.8b
Yasuo Takehana	President	2.4yrs	geen gegevens	0.037% ¥ 61.4m
Takahide Kitahara	GM of Financial Management Department	12.4yrs	geen gegevens	0.020% ¥ 33.9m
Yoshio Furihata	Senior Advisor & Director	14.4yrs	geen gegevens	0.029% ¥ 48.0m
Keiji Fukushima	Executive VP & Director	12.4yrs	geen gegevens	0.027% ¥ 44.2m
Tetsu Takayama	Executive MD & Director	4.4yrs	geen gegevens	0.035% ¥ 58.6m
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	2.4yrs	geen gegevens	0.0039% ¥ 6.4m
Keiji Miyazawa	GM of Research Division & Director	2.4yrs	geen gegevens	0.0041% ¥ 6.7m

4.4yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren management: 4547's management team is considered experienced (4.4 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mutsuo Kanzawa	Chairman & CEO	42.4yrs	geen gegevens	3.49% ¥ 5.8b
Yasuo Takehana	President	12.8yrs	geen gegevens	0.037% ¥ 61.4m
Takahide Kitahara	GM of Financial Management Department	6.4yrs	geen gegevens	0.020% ¥ 33.9m
Yoshio Furihata	Senior Advisor & Director	16.4yrs	geen gegevens	0.029% ¥ 48.0m
Keiji Fukushima	Executive VP & Director	12.4yrs	geen gegevens	0.027% ¥ 44.2m
Tetsu Takayama	Executive MD & Director	10.4yrs	geen gegevens	0.035% ¥ 58.6m
Hiroshi Noake	GM of Pharmaceutical Sales Headquarters & Director	2.4yrs	geen gegevens	0.0039% ¥ 6.4m
Keiji Miyazawa	GM of Research Division & Director	2.4yrs	geen gegevens	0.0041% ¥ 6.7m
Shigetaka Shimizu	Independent Outside Director	10.4yrs	geen gegevens	0.0086% ¥ 14.3m
Sayuri Uchikawa	Independent Outside Director	4.4yrs	geen gegevens	0.0039% ¥ 6.4m
Minoru Nomura	Independent Outside Director	8.4yrs	geen gegevens	0.012% ¥ 19.1m
Yoshinori Otsuki	Independent Outside Director	2.4yrs	geen gegevens	0.0027% ¥ 4.5m

9.4yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: 4547's board of directors are considered experienced (9.4 years average tenure).

Kissei Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Less than half of directors are independent

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Upcoming dividend of JP¥45.00 per share

Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 05, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00

Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00

Final dividend of JP¥45.00 announced

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit

Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2024

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Upcoming dividend of JP¥41.00 per share

Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 07, 2024

Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00

Third quarter 2024 earnings released: EPS: JP¥59.18 (vs JP¥72.45 in 3Q 2023)

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 2024

New major risk - Revenue and earnings growth

Price target increased by 7.4% to JP¥3,650

Kissei Pharmaceutical Co., Ltd. and Maruishi Pharmaceutical Co., Ltd. Announces KORSUVA®? IV Injection Syringe for Dialysis 17.5ug, 25.0ug to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis

Consensus EPS estimates fall by 10%

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 30, 2024

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: JP¥52.66 (vs JP¥36.67 in 2Q 2023)

Now 20% undervalued after recent price drop

Price target increased by 7.1% to JP¥3,400

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2023

Upcoming dividend of JP¥41.00 per share at 2.4% yield

Price target increased by 8.9% to JP¥3,350

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Kissei Pharmaceutical Co., Ltd. Announces Withdrawal of Application for Marketing Approval for Rovatirelin for the Treatment of Spinocerebellar Degeneration in Japan

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Kissei Pharmaceutical Co., Ltd. (TSE:4547) announces an Equity Buyback for 2,000,000 shares, representing 4.34% for ¥6,000 million.

Upcoming dividend of JP¥40.00 per share at 3.1% yield

Kissei Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings released: EPS: JP¥72.45 (vs JP¥25.00 in 3Q 2022)

Consensus forecasts updated

Now 20% undervalued

Kissei Pharmaceutical Co., Ltd. Receives Marketing Authorization Approval in Japan for TAVALISSE Tab. 100Mg and 150Mg, an Oral Spleen Tyrosine Kinase Inhibitor

Kissei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Kissei Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter and Dividend Guidance for Year Ending of March 31, 2023, Payable Date on December 2, 2022

Kissei Pharmaceutical Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ending September 30, 2022

Upcoming dividend of JP¥40.00 per share

Kissei Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Kissei Pharmaceutical Co., Ltd. Provides Earning Guidance for the First Half Ending September 30, 2022 and Full Year Ending March 31, 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Kissei Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022

Consensus forecasts updated

Kissei Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

Kissei Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 10, 2022

Upcoming dividend of JP¥28.00 per share

Third quarter 2022 earnings: EPS exceeds analyst expectations

Kissei Pharmaceutical Co., Ltd. Releases Positive Topline Results from Its Phase 3 Clinical Trial in Japan

Second quarter 2022 earnings released: EPS JP¥43.85 (vs JP¥57.18 in 2Q 2021)

Kissei Pharmaceutical Co., Ltd. announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

Upcoming dividend of JP¥28.00 per share